PHASE I PK AND PD STUDY OF CCI-779 IN ADVANCED MALIGNANCIES

CCI-779 在晚期恶性肿瘤中的 I 期 PK 和 PD 研究

• 批准号: 7607551
• 负责人: GEORGE WILDING
• 金额: $ 0.37万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607551
• 关键词: Adverse effects; CCI-779; Cancer Cell Growth; Computer Retrieval of Information on Scientific Projects Database; Dose; Enzymes; Funding; Grant; Institution; Lymphoma; Malignant Neoplasms; Operative Surgical Procedures; Patients; Phase; Phase I Clinical Trials; Research; Research Personnel; Resources; Solid Neoplasm; Source; United States National Institutes of Health; cell growth; liver function

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Temsirolimus may have different effects in patients who have changes in their liver function. This Phase I trial is studying the side effects and best dose of temsirolimus in treating patients with metastatic solid tumor or lymphoma that cannot be removed by surgery who have different levels of liver function.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 (摘自ClinicalTrials.gov网站) 替西罗莫司可能通过阻断细胞生长所需的一些酶来阻止癌细胞的生长。替西罗莫司对肝功能有改变的患者可能有不同的影响。 这项第一阶段试验正在研究替西罗莫斯治疗转移性实体肿瘤或淋巴瘤患者的副作用和最佳剂量，这些患者无法通过手术切除，这些患者具有不同程度的肝功能。